Latest Headlines

Latest Headlines

Merck won't change endpoint in new Vytorin trial

Merck resisted a steering committee's recommendation to change the primary endpoint in a new clinical trial of its cholesterol drug Vytorin in chronic kidney patients, three years after an endpoint

Judge refuses to dismiss Schering shareholder suit

Will former Schering-Plough management end up on the witness stand, talking about the controversial Enhance trial? A shareholder suit could force them there--and a federal judge has refused the

Niaspan trounces Zetia, spurring debate

Well, analysts were right about that much-anticipated cholesterol drug study. Abbott Laboratories' Niaspan pill did indeed beat out Merck's Zetia at unclogging arteries, according to study results

Lawsuit: Schering execs sat on Vytorin results

Back when Merck and Schering-Plough finally released the results of their star-crossed cholesterol drug study Enhance in early 2008, industry observers wondered just how much the companies themselves

Merck, Schering settle Vytorin claims for $5.4M

Merck and Schering-Plough got out of 35 state investigations of the Enhance trial only $5.4 million poorer. The drugmakers agreed to pay the states' investigative costs--and that's it. No admission

Judge: CafePharma posts stay in Schering case

It looks as if CafePharma is getting another 15 minutes of fame. A federal judge will allow anonymous postings on the site's forum to remain as evidence in a suit against Schering-Plough. That

Vytorin debate heats up ESC

There's controversy brewing at the European Society of Cardiology meeting in Munich. Today, the now-infamous SEAS study, in which Vytorin not only missed its primary endpoint but appeared to be

Hassan's advice for hard times

When the interview subject is adversity, who better to question than Schering-Plough's Fred Hassan, who's seen his share this year? BusinessWeek chatted with the Schering CEO about dealing with hard

Vytorin, Zetia scrips drop 11% in April

Prescriptions for Vytorin and Zetia, Merck/Schering-Plough's co-marketed cholesterol meds, fell off by 11 percent just during the month of April, to less than 2.5 million from 2.8 million in March.

Should Hassan forfeit $13 million?

Should Fred Hassan (photo) give back his bonus? That's what Forbes is asking this week, saying that the